Skip to main content
NCBI home page
Gut logoLink to Gut
. 1994 Nov;35(11):1562–1566. doi: 10.1136/gut.35.11.1562

High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease.

N Banatvala 1, G R Davies 1, Y Abdi 1, L Clements 1, D S Rampton 1, J M Hardie 1, R A Feldman 1
PMCID: PMC1375612  PMID: 7828973

Abstract

A high prevalence of metronidazole resistance in Helicobacter pylori is reported in developing countries. This study examined whether migrants referred for diagnostic gastroscopy at a United Kingdom centre (n = 54), had a higher prevalence of metronidazole resistance than subjects born in the United Kingdom attending endoscopy (n = 46). Records of nitroimidazole treatment prescribed in the United Kingdom was obtained in 83 patients to find out if there was an association between H pylori metronidazole resistance and previous ingestion of either metronidazole or tinidazole. The prevalence of metronidazole resistant isolates varied according to country of birth: Bangladesh (90%, 27 of 30), other countries (67%, 16 of 24), and United Kingdom (37%, 17 of 46) (p < 0.001). Among those born in the United Kingdom, women were more likely to harbour resistant H pylori than men (54% v 18% respectively, p = 0.01) and more likely to have a history of previous nitroimidazole ingestion (41% v 11% respectively, p = 0.02). Patients previously exposed to either metronidazole or tinidazole were more likely to harbour resistant strains (84% (27 of 32) v 41% (21 or 51), p < 0.0001). The distribution of gastroduodenal disease, assessed endoscopically, was not affected by metronidazole resistance status.

Full text

PDF
1562

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azhar M. A., Ahasan H. A., Chowdhury M. A., Rafiqueuddin A. K. Over the counter drugs in Bangladesh. BMJ. 1993 Nov 27;307(6916):1422–1422. doi: 10.1136/bmj.307.6916.1422-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Becx M. C., Janssen A. J., Clasener H. A., de Koning R. W. Metronidazole-resistant Helicobacter pylori. Lancet. 1990 Mar 3;335(8688):539–540. doi: 10.1016/0140-6736(90)90772-w. [DOI] [PubMed] [Google Scholar]
  3. Bell G. D., Powell K., Burridge S. M., Pallecaros A., Jones P. H., Gant P. W., Harrison G., Trowell J. E. Experience with 'triple' anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther. 1992 Aug;6(4):427–435. doi: 10.1111/j.1365-2036.1992.tb00556.x. [DOI] [PubMed] [Google Scholar]
  4. Bryan L. E., O'Hara K., Wong S. Lipopolysaccharide changes in impermeability-type aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984 Aug;26(2):250–255. doi: 10.1128/aac.26.2.250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Coia J. E., Browning L., Haines L., Birkbeck T. H., Platt D. J. Comparison of enterotoxins and haemolysins produced by methicillin-resistant (MRSA) and sensitive (MSSA) Staphylococcus aureus. J Med Microbiol. 1992 Mar;36(3):164–171. doi: 10.1099/00222615-36-3-164. [DOI] [PubMed] [Google Scholar]
  6. Dorman C. J., Chatfield S., Higgins C. F., Hayward C., Dougan G. Characterization of porin and ompR mutants of a virulent strain of Salmonella typhimurium: ompR mutants are attenuated in vivo. Infect Immun. 1989 Jul;57(7):2136–2140. doi: 10.1128/iai.57.7.2136-2140.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Glupczynski Y., Burette A., De Koster E., Nyst J. F., Deltenre M., Cadranel S., Bourdeaux L., De Vos D. Metronidazole resistance in Helicobacter pylori. Lancet. 1990 Apr 21;335(8695):976–977. doi: 10.1016/0140-6736(90)91043-a. [DOI] [PubMed] [Google Scholar]
  8. Megraud F., Bonnet F., Garnier M., Lamouliatte H. Characterization of "Campylobacter pyloridis" by culture, enzymatic profile, and protein content. J Clin Microbiol. 1985 Dec;22(6):1007–1010. doi: 10.1128/jcm.22.6.1007-1010.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Musher D. M., Baughn R. E., Templeton G. B., Minuth J. N. Emergence of variant forms of Staphylococcus aureus after exposure to gentamicin and infectivity of the variants in experimental animals. J Infect Dis. 1977 Sep;136(3):360–369. doi: 10.1093/infdis/136.3.360. [DOI] [PubMed] [Google Scholar]
  10. Rautelin H., Seppälä K., Renkonen O. V., Vainio U., Kosunen T. U. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother. 1992 Jan;36(1):163–166. doi: 10.1128/aac.36.1.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rauws E. A., Tytgat G. N. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet. 1990 May 26;335(8700):1233–1235. doi: 10.1016/0140-6736(90)91301-p. [DOI] [PubMed] [Google Scholar]
  12. Ravizzola G., Pirali F., Paolucci A., Terlenghi L., Peroni L., Colombi A., Turano A. Reduced virulence in ciprofloxacin-resistant variants of Pseudomonas aeruginosa strains. J Antimicrob Chemother. 1987 Dec;20(6):825–829. doi: 10.1093/jac/20.6.825. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES